Fig. 1 · Structure

Documents & Downloads

A 438079 hydrochloride

Cat. No. A14983 CAS 899431-18-6

P2X7 receptor antagonist

A 438079 Hcl is a competitive P2X7 receptor antagonist (pIC50 = 6.9 for the inhibition of Ca2+ influx in the human recombinant P2X7 cell line).

In Stock

Publications for A 438079 hydrochloride

1 publication citing this product

  1. Zhihua Yi, .et al. , Front Pharmacol, 2018, 9: 593 PMID: 29950989

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

A438079 inhibited ATP-evoked currents in a recombinant human P2X7 receptor construct. Mutagenesis combined with docking supports an intersubunit allosteric binding model; an A438079-bound crystal structure was not obtained. The tested material was described as hydrochloride hydrate. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
P2X7 receptor pIC50 6.9

A 438079 hydrochloride Research Summary

This section summarizes 1 in vitro study and 1 in vivo study of A 438079 hydrochloride from 2 published references.

A 438079 hydrochloride In Vitro Studies

Functional antagonism and mapping of the P2X7 antagonist pocket

Cell-based study · Xenopus oocytes expressing human P2X7-2Nβ receptors, receptor chimeras/point mutants and human P2X1 control [1]

ATP-current inhibition and pocket mutations, interpreted with docking, support an allosteric binding model. This is a recombinant functional assay, not direct structural proof.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
ATP EC90-evoked peak current inhibition at P2X7-2NβpIC50 6.0 ± 0.05 (mean ± SEM; n = 4)[1]
ATP EC90-evoked current inhibition at T94VpIC50 <4 (n = 3)[1]
ATP EC90-evoked current inhibition at D92ApIC50 <4 (n = 3)[1]

Literature-Reported Treatment Conditions

Treatment concentration
Concentration-response testing; 3 μM illustrated in Figure 1B. These are assay concentrations, not organism doses.
Exposure duration
ATP applied for 3 s at 3–5 min intervals; antagonist bath-perfused and coapplied.
Method
Voltage clamp at −60 mV in divalent-free ND96; receptor-specific ATP EC90 challenge.
Co-treatment
ATP agonist challenge; A740003 tested separately as a comparator.
Reported limits
Antagonist solvent and exact pre-exposure duration not specified in the acquired pharmacology methods.
Methods and source locations

Compound reported in the paper: A438079; Compound label in the paper: A438079

Supports active-compound pharmacology with reported hydrate qualifier; no salt conversion, hydration equivalence or Adooq lot validation.

Figure 1B–D; Table 1 (P2X7-2Nβ row); Figure 4A–B; Table 2 (T94V and D92A rows); Materials and Methods: Pharmacological Characterization/Data Analysis; Results: docking and pocket mutants

ATP EC90-evoked peak current inhibition at P2X7-2Nβ: Two-electrode voltage clamp; Hill fits to individual inhibition curves — Table 1, P2X7-2Nβ row; Data Analysis

ATP EC90-evoked current inhibition at T94V: Two-electrode voltage clamp — Table 2, T94V row; Figure 4A

ATP EC90-evoked current inhibition at D92A: Two-electrode voltage clamp — Table 2, D92A row; Figure 4A

A 438079 hydrochloride In Vivo Studies

In male mice, one week of intracerebroventricular A438079 hydrochloride infusion increased pilocarpine-induced behavioral seizure susceptibility relative to saline controls. The authors reported no behavioral effect in P2X7-knockout mice. This result limits generalization of seizure protection across models. [2]

Increased pilocarpine-induced seizure susceptibility after A438079 infusion

Animal study · Male WT C57BL/6J and P2X7-knockout mice; pilocarpine-induced behavioral seizures [2]

A438079 increased behavioral seizure susceptibility in WT mice. The lack of an effect in knockout animals was reported without displayed data. This adverse direction is specific to the tested model and regimen.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Behavioral seizure score after pilocarpineGroup comparison Increased versus saline-infused WT; P < 0.05; n = 7; mean ± SEM[2]

Conditions shared by the study groups

Route
Intracerebroventricular infusion via osmotic minipump
Frequency
Continuous infusion
Treatment course
1 week before pilocarpine challenge; behavioral monitoring for 5 h
Vehicle
Saline
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
WT mice receiving A438079 before pilocarpine
10 μM infusion solution; not a body-weight dose
Saline-infused WT mice challenged with pilocarpine; P2X7-knockout comparison reported in ResultsHigher behavioral seizure score than saline-infused WT controls (P < 0.05; Figure 4A n = 7; data mean ± SEM). Antagonists did not affect scores in knockout mice (data not shown).[2]
WT mice receiving A438079 before pilocarpine
Model: Male C57BL/6J WT mice, 60–90 days old
Reported limits: Total delivered A438079 amount and group-specific raw behavioral scores were not extracted; no exact score inferred from bars. Randomization/blinding not stated in acquired relevant methods.
Methods and source locations

Compound reported in the paper: A438079 hydrochloride; Compound label in the paper: A438079

Compound/form matched; independent supplier material, not an Adooq lot test.

Results: P2X7R antagonists increase PILO-induced seizure susceptibility in WT mice; Figure 4A and caption; Methods: animals, drug infusion, behavioral seizure activity and Statistics

Behavioral seizure score after pilocarpine: Ordinal behavioral scoring over 5 h; score range 0–6; general statistical methods: two-tailed t test or one-way ANOVA with Bonferroni comparisons — Figure 4A and caption; Results antagonist paragraph; Methods: Behavioral seizure activity/Statistics

WT mice receiving A438079 before pilocarpine · Results: P2X7R antagonists increase PILO-induced seizure susceptibility in WT mice; Figure 4A and caption; Methods: animals, drug infusion, behavioral seizure activity and Statistics

Specifications

Manufacturer Adooq Bioscience
Actions Antagonist
CAS Number 899431-18-6
Applications P2X7 receptor antagonist
Formula C13H10Cl3N5
Molecular Weight 342.61
SMILES
C1=CC(=C(C(=C1)Cl)Cl)C2=NN=NN2CC3=CN=CC=C3.Cl

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 55 mg/mL (160.53 mM)
Water 55 mg/mL (160.53 mM)
Ethanol Warmed: 18 mg/mL (52.53 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
28 mg/mL
Vehicle
Saline

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

A 438079 hydrochloride Research References

  1. [1] Allsopp RC, Dayl S, Bin Dayel A, et al. Mapping the Allosteric Action of Antagonists A740003 and A438079 Reveals a Role for the Left Flipper in Ligand Sensitivity at P2X7 Receptors. Molecular pharmacology (2018). PMID: 29535152 DOI: 10.1124/mol.117.111021 Source material
  2. [2] Kim JE, Kang TC. The P2X7 receptor-pannexin-1 complex decreases muscarinic acetylcholine receptor-mediated seizure susceptibility in mice. The Journal of clinical investigation (2011). PMID: 21505260 DOI: 10.1172/jci44818 Source material

Publications

1 publication citing this product

  1. Zhihua Yi, .et al. , Front Pharmacol, 2018, 9: 593 PMID: 29950989

Added to your cart

View Cart Checkout
Loading...